{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:31:39Z","timestamp":1761006699639,"version":"build-2065373602"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,10,17]],"date-time":"2003-10-17T00:00:00Z","timestamp":1066348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"British Biological Science Research Council"},{"name":"Parkinson's Disease Society"},{"name":"National Parkinson's Disease Foundation"},{"name":"Knoll Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2004,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Long\u2010term treatment of Parkinson's disease (PD) with levodopa (<jats:sc>L<\/jats:sc>\u2010dopa) induces dyskinesia that, once established, is provoked by each dose of <jats:sc>L<\/jats:sc>\u2010dopa or a dopamine (DA) agonist. In contrast, monoamine reuptake inhibitors may reverse motor deficits in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine (MPTP)\u2010treated primates without provoking established involuntary movements. We now examine whether the potent monoamine reuptake blocker BTS 74 398 induces established dyskinesia in MPTP\u2010treated common marmosets primed previously with <jats:sc>L<\/jats:sc>\u2010dopa and whether co\u2010administration of BTS 74 398 with <jats:sc>L<\/jats:sc>\u2010dopa potentiates motor behaviour and dyskinesia induced by acute <jats:sc>L<\/jats:sc>\u2010dopa treatment. Administration of BTS 74 398 (2.5, 5.0, or 10.0 mg\/kg, p.o.) in MPTP\u2010treated common marmosets increased locomotor activity and reduced motor disability in a dose\u2010related manner but did not provoke involuntary movements. BTS 74 398 (2.5, 5.0, or 10.0 mg\/kg p.o.) co\u2010administered with a threshold dose of <jats:sc>L<\/jats:sc>\u2010dopa (2.5 mg\/kg p.o.) did not evoke a motor response or induce dyskinesia. Similarly, concomitant administration of BTS 74 398 (5.0 mg\/kg p.o.) with a submaximal <jats:sc>L<\/jats:sc>\u2010dopa dose (12.5 mg\/kg p.o.) did not potentiate the motor response produced by <jats:sc>L<\/jats:sc>\u2010dopa alone and there was no alteration in the dyskinesia provoked by <jats:sc>L<\/jats:sc>\u2010dopa challenge. BTS 74 398 reverses motor abnormalities in MPTP\u2010treated marmosets without evoking established dyskinesia but no additive improvement occurs when administered in combination with <jats:sc>L<\/jats:sc>\u2010dopa. The lack of synergy with <jats:sc>L<\/jats:sc>\u2010dopa may suggest different sites of drug action. \u00a9 2003 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10596","type":"journal-article","created":{"date-parts":[[2004,1,21]],"date-time":"2004-01-21T05:01:49Z","timestamp":1074661309000},"page":"15-21","source":"Crossref","is-referenced-by-count":17,"title":["The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP\u2010treated primates"],"prefix":"10.1002","volume":"19","author":[{"given":"Matthew J.","family":"Hansard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon C.","family":"Cheetham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,1,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.9.1034"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855001-00004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.573"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090107"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.1.162"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199619030-00002"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.39.12.1219"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb05751.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1977.tb05750.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.44.4.352"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1983.04050120038004"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.8.1092"},{"key":"e_1_2_6_17_2","first-page":"256","article-title":"Behavioural effects of the monoamine reuptake inhibitor, BTS 74 398, in rats and mice","volume":"123","author":"Jackson HC","year":"1998","journal-title":"Br J Pharmacol"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.039743"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)02268-9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10238"},{"key":"e_1_2_6_21_2","first-page":"224","article-title":"BTS 74 398: a novel monoamine reuptake inhibitor for the treatment of Parkinson's disease","volume":"123","author":"Cheetham S","year":"1998","journal-title":"Brit J Pharmacol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(84)90467-1"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870100606"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120616"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0022-3565(25)20396-2","article-title":"Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L\u2010dopa in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010treated monkeys","volume":"259","author":"Gomez\u2010Mancilla B","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3565(25)39350-X","article-title":"Differential effect of selective D\u20101 and D\u20102 dopamine receptor agonists on levodopa\u2010induced dyskinesia in 1\u2010methyl\u20104\u2010phenyl\u20101,2,3,6\u2010tetrahydropyridine\u2010exposed monkeys","volume":"267","author":"Blanchet P","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90783-3"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90556-J"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244865"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90026-4"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.6.10.949"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01491-2"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(19990301)31:3<178::AID-SYN2>3.0.CO;2-M"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.721516.x"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(89)90012-2"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1993.tb07469.x"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10596","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10596","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10596","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T09:49:18Z","timestamp":1760953758000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["10.1002\/mds.10596"],"URL":"https:\/\/doi.org\/10.1002\/mds.10596","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"type":"print","value":"0885-3185"},{"type":"electronic","value":"1531-8257"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}